Pre-made Emerfetamab benchmark antibody ( Bispecific scFv, anti-CD33;CD3E therapeutic antibody, Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-176

Pre-Made Emerfetamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-176-1mg 1mg Inquiry
GMP-Bios-ab-176-10mg 10mg Inquiry
GMP-Bios-ab-176-100mg 100mg Inquiry
GMP-Bios-ab-176-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Emerfetamab biosimilar, Bispecific scFv, Anti-CD33;CD3E Antibody: Anti-p67/SIGLEC3/SIGLEC-3;T3E/TCRE/IMD18 therapeutic antibody
INN Name Emerfetamab
TargetCD33;CD3E
FormatBispecific scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommended2021
CompaniesAmgen
Conditions Approvedna
Conditions ActiveAcute myeloid leukemia
Conditions Discontinuedna
Development TechBiTE Technology